Barclays PLC Adaptimmune Therapeutics PLC Transaction History

Barclays PLC

$854 Billion
Q3 2025

A detailed history of Barclays PLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Barclays PLC holds 2,534 shares of ADAP stock, worth $76. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,534

Previous 2,534 -0.0%

Holding current value

$76

Previous $1,000 100.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$0.22 - $0.32 $10,457 - $15,210	-47,534 Reduced 94.94%	2,534 $1,000
Q1 2025 May 15, 2025	BUY	$0.2 - $0.65 $1 - $4	7 Added 0.01%	50,068 $10,000
Q2 2023 Aug 03, 2023	BUY	$0.9 - $1.51 $45,054 - $75,592	50,061 New	50,061 $46,000
Q3 2022 Nov 03, 2022	BUY	$1.06 - $2.41 $92,629 - $210,600	87,386 Added 34.58%	340,068 $366,000
Q2 2022 Aug 12, 2022	BUY	$1.33 - $2.28 $336,067 - $576,114	252,682 New	252,682 $430,000

Q4 2021 Feb 14, 2022	SELL	$3.5 - $5.68 $38 - $62	-11 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$3.44 - $6.37 $130 - $242	-38 Reduced 77.55%	11 $0
Q2 2021 Aug 13, 2021	SELL	$3.86 - $5.78 $31,420 - $47,049	-8,140 Reduced 99.4%	49 $0
Q1 2021 May 13, 2021	BUY	$4.9 - $6.83 $984 - $1,372	201 Added 2.52%	8,189 $43,000
Q4 2020 Feb 11, 2021	BUY	$4.0 - $9.2 $2,352 - $5,409	588 Added 7.95%	7,988 $43,000
Q1 2020 May 13, 2020	BUY	$1.2 - $4.52 $8,248 - $31,070	6,874 Added 1306.84%	7,400 $20,000
Q4 2019 Feb 10, 2020	SELL	$0.72 - $1.43 $804 - $1,597	-1,117 Reduced 67.99%	526 $1,000
Q3 2019 Nov 14, 2019	BUY	$1.43 - $3.81 $2,349 - $6,259	1,643 New	1,643 $2,000
Q2 2019 Aug 14, 2019	SELL	$3.23 - $5.41 $2,813 - $4,712	-871 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$3.63 - $6.06 $2,178 - $3,635	600 Added 221.4%	871 $4,000
Q4 2018 Feb 14, 2019	BUY	$3.76 - $14.16 $800 - $3,016	213 Added 367.24%	271 $2,000
Q3 2018 Nov 14, 2018	SELL	$8.27 - $13.56 $289,888 - $475,318	-35,053 Reduced 99.83%	58 $1,000
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $8,752 - $11,541	-840 Reduced 2.34%	35,111 $417,000
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $6,042 - $9,837	851 Added 2.42%	35,951 $403,000
Q4 2017 Feb 14, 2018	SELL	$6.68 - $8.74 $16,700 - $21,850	-2,500 Reduced 6.65%	35,100 $234,000
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $185,368 - $335,768	37,600	37,600 $308,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

42M

Call Options Held

139K

Put Options Held

144K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $4.9M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account